MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line

Oncogene

Volumn 26, Issue 55, 2007, Pages 7675-7683

  Chetty, C ^a   Bhoopathi, P ^a   Lakka, S S ^a   Rao, J S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Apoptosis; CD95 (APO Fas); Cytochrome c; Fas L; MMP 2; TIMP 3

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS ANTIBODY; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GELATINASE A; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; UPREGULATION; XENOGRAFT;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MICE; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

ADENOVIRIDAE;

EID: 36849042742     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210584     Document Type: Article

References (32)

1. Ahonen M, la-Aho R, Baker AH, George SJ, Grenman R, Saarialho-Kere U et al. (2002). Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther 5: 705-715.
2. Baker AH, Edwards DR, Murphy G. (2002). Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115: 3719-3727.
3. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. (1999). Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79: 1347-1355.
4. Baker AH, Zaltsman AB, George SJ, Newby AC. (1998). Divergent effects of tissue inhibitor of metalloproteinase-1, -2 or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 101: 1478-1487.
5. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A et al. (1993). Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197-250.
6. Bond M, Murphy G, Bennett MR, Amour A, Knauper V, Newby AC et al. (2000). Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity. J Biol Chem 275: 41358-41363.
7. Bond M, Murphy G, Bennett MR, Newby AC, Baker AH. (2002). Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 277: 13787-13795.
8. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC et al. (2002). Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86: 1864-1870.
9. Brew K, Dinakarpandian D, Nagase H. (2000). Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477: 267-283.
10. Brown PD, Giavazzi R. (1995). Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 6: 967-974.
11. Cawston TE. (1995). Proteinases and inhibitors. Br Med Bull 51: 385-401.
12. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, Lakka SS. (2006). Adenovirus-mediated siRNA against MMP-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 5: 2289-2299.
13. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. (1995). FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512.
14. Drynda A, Quax PH, Neumann M, van der Laan WH, Pap G, Drynda S et al. (2005). Gene transfer of tissue inhibitor of metalloproteinases-3 reverses the inhibitory effects of TNF-alpha on Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. J Immunol 174: 6524-6531.
15. Evans JD, Stark A, Johnson CD, Daniel F, Carmichael J, Buckels J et al. (2001). A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 85: 1865-1870.
16. Fata JE, Leco KJ, Voura EB, Yu HY, Waterhouse P, Murphy G et al. (2001). Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest 108: 831-841.
17. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. (1997). Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74: 111-122.
18. Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. (2000). Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 105: 143-150.
19. Hengartner MO. (2000). The biochemistry of apoptosis. Nature 407: 770-776.
20. Kang SH, Choi HH, Kim SG, Jong HS, Kim NK, Kim SJ et al. (2000). Transcriptional inactivation of the tissue inhibitor of metalloproteinase-3 gene by dna hypermethylation of the 5′-CpG island in human gastric cancer cell lines. Int J Cancer 86: 632-635.
21. Khong HT, Restifo NP. (2002). Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 3: 999-1005.
22. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES et al. (1997). Cytochrome-c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489.
23. Li WQ, Zafarullah M. (1998). Oncostatin M up-regulates tissue inhibitor of metalloproteinases-3 gene expression in articular chondrocytes via de novo transcription, protein synthesis, and tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms. J Immunol. 161: 5000-5007.
24. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome-c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490.
25. Medema JP, Toes RE, Scaffidi C, Zheng TS, Flavell RA, Melief CJ et al. (1997). Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur J Immunol 27: 3492-3498.
26. Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC. (2001). Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug. Expert Opin Investig Drugs 10: 1075-1084.
27. Nyormoi O, Mills L, Bar-Eli M. (2003). An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 10: 558-569.
28. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687.
29. Spurbeck WW, Ng CY, Strom TS, Vanin EF, Davidoff AM. (2002). Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 100: 3361-3368.
30. Strand S, Vollmer P, van den AL, Gottfried D, Alla V, Heid H et al. (2004). Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 23: 3732-3736.
31. Tanaka M, Suda T, Takahashi T, Nagata S. (1995). Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 14: 1129-1135.
32. Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T et al. (1999). Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 35: 1462-1465.